Bonn suspends licence for Astra's star drug
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.ASTRA, the Swedish drug group, said yesterday that the German regulatory authorities had temporarily suspended the licence for the intravenous injection of its anti-ulcer drug, Losec.
Losec is Astra's star new drug, and is seen as potentially more effective for ulcer treatments than Zantac and Tagamet since it can be used with antibiotics to treat the bacterial infections believed to be the cause of a large number of ulcers.
The ban is the latest twist in a simmering row between Astra and the German authorities. The latter say there have been several cases of severe side-effects as a result of patients using the injected form of the drug.
Astra denies the allegations and the EC Committee for Proprietary Medicinal Products said recently sales could go ahead if a warning note was attached to the injectable form.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments